Seasons greetings from Ab Initio!
Ab Initio Pharma
Pharmaceutical Manufacturing
Camperdown, NSW 1,326 followers
A facility that provides R&D services, formulation support and GMP product manufacture that meets regulatory guidelines.
About us
At Ab Initio Pharma, we are committed to empowering pharmaceutical companies by offering comprehensive contract development and manufacturing (CDMO) services tailored to complex dosage forms. From early-stage development through to clinical and registration, we specialise in delivering cGMP-compliant solutions that ensure product quality, safety, and regulatory compliance.
- Website
-
https://www.ab-initio-pharma.com/
External link for Ab Initio Pharma
- Industry
- Pharmaceutical Manufacturing
- Company size
- 11-50 employees
- Headquarters
- Camperdown, NSW
- Type
- Privately Held
- Founded
- 2019
- Specialties
- Inhalation pharmaceuticals, Non-sterile formulations, R&D, CDMO, Complex dosage forms, and cGMP
Locations
-
Primary
Get directions
Camperdown, NSW 2050, AU
Employees at Ab Initio Pharma
Updates
-
Ab Initio Pharma reposted this
Australia and New Zealand are ranked one of the best places in the world to conduct clinical trials. Download our free whitepaper to find out why Australia and New Zealand are attractive to global sponsors.
-
Ab Initio Pharma reposted this
Don't forget to drop by booth #210 and chat to Mathew Leslie and the team to learn how we can help you develop your NCEs and biomolecules into clinic ready OINDP products #formulation #GMP Drug Delivery to the Lungs Conference (DDL) #DDL2024
-
-
Don't forget to drop by booth #210 and chat to Mathew Leslie and the team to learn how we can help you develop your NCEs and biomolecules into clinic ready OINDP products #formulation #GMP Drug Delivery to the Lungs Conference (DDL) #DDL2024
-
-
Ab Initio’s CSO, YY (Dr Hui Xin Ong) talks about nasal drug delivery of RNA using Tetratherix matrix at Drug Delivery to the Lungs Conference (DDL) 2024
-
-
Did you know Ab Initio develops inhaled biologics? Learn more at DDL 2024 · Learn about Ab Initio's CDMO services for OINDP services. · Listen to our CSO, Dr Ong (YY) talk about inhaled nasal RNA therapy on Wednesday afternoon · Read our poster on how we helped a client develop inhaled clinic ready oligonucleotide · Visit us at Booth #210 https://lnkd.in/eUzGQNb8
Did You Know Ab Initio Leads the Way in Developing Inhaled and Nasal Biologics?: Meet with our CSO, YY at DDL 2024 — Ab-initio pharma
ab-initio-pharma.com
-
Join Ab Initio Pharma At DDL 2024 and learn how we are shaping the future of inhaled therapies 📍 Visit us on Stand 210 to discuss how we can help you from bench to clinic with our integrated respiratory CDMO and GMP services 🎤 Listen to Chief Scientific Officer, Dr. Hui Xin Ong (YY), speak on "Enhancing the Intranasal Delivery of mRNA Therapeutics Using a Novel Thermosensitive Polymer." This presentation is part of Session 3: Gene Therapy and Biologics for the Lungs, scheduled for Wednesday, December 11, 2024, from 4:30 PM to 5:50 PM. 🖼️ Read our poster on how we were revolutionising biologics with the development of clinic ready inhaled oligonucleotide formulations. Learn more at https://lnkd.in/ewvx5xXU
Join Ab Initio Pharma at DDL 2024: Shaping the Future of Inhaled Therapies — Ab-initio pharma
ab-initio-pharma.com
-
BioBeacon, a fantastic initiative by ARCS Australia dedicated to promoting and showcasing Australian life sciences startups. https://lnkd.in/g2GeKC-i
Exciting News: BioBeacon Website is Now Live We’re thrilled to announce the launch of the BioBeacon website – biobeacon.com.au. BioBeacon is your destination for everything lifesciences innovation, providing a platform to: Build the profile of emerging lifesciences startups. Showcase founders and their inspiring entrepreneurial journeys. Explore groundbreaking new technologies shaping the future of health. But that’s just the beginning! ARCS Australia has been hard at work on a podcast series that tracks the incredible journeys of the startups featured in the first BioBeacon cohort, unveiled at the 2024 ARCS Australia Conference. This series will launch in early 2025, bringing you behind-the-scenes insights into their challenges, triumphs, and innovations. Also coming in early 2025, ARCS Australia will launch dedicated resources to help lifesciences startups launch, establish, and scale. Stay tuned for updates as BioBeacon continues to shine a light on the innovators driving the future of medicine. Visit biobeacon.com.au to learn more! #BioBeacon #LifeSciencesInnovation #ARCSAustralia #Entrepreneurship #FutureOfMedicine Tim Boyle Stefan Mazy DermR Health Stuart Fraser Culturon® ShanShan Wang Roam Technologies (roamtech.ai) Nan Z. NGB Innovation Jay Flack Paul Young Ab Initio Pharma Robert Yearsley Warren Bingham (GAICD) ARIA Research Robert Gorkin Nick Northcott Eudaemon Technologies Chris Bladen Zymedyne Therapeutics Jeremy K. iiShield https://lnkd.in/g2GeKC-i